Sorrento Therapeutics
Biotechnology Research • 
San Diego, California, United States • 101-200 Employees
Company overview
| Headquarters | 4955 Directors Place, San Diego, California 92121, US |
| Phone number | +18582034100 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biopharma, Diagnostics, Cancer, Infectious Diseases, Covid-19, Non-Opioid Pain Management |
| Founded | 2009 |
| Employees | 101-200 |
| Socials |
Key Contact at Sorrento Therapeutics
Sorrento Therapeutics Email Formats
Sorrento Therapeutics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@sorrentotherapeutics.com), used 61.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@sorrentotherapeutics.com | 61.1% |
{first name}{last name} | johndoe@sorrentotherapeutics.com | 24.1% |
{last name}{last name} | doedoe@sorrentotherapeutics.com | 7.4% |
{first initial} | j@sorrentotherapeutics.com | 3.7% |
{f2}{last name} | {f2}doe@sorrentotherapeutics.com | 3.7% |
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
Sorrento Therapeutics revenue & valuation
| Annual revenue | $64,300,000 |
| Revenue per employee | $596,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $205,700,000 |
| Total funding | $25,000,000 |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Sorrento Therapeutics has 40 employees across 11 departments.
Departments
Number of employees
Sorrento Therapeutics Tech Stack
Discover the technologies and tools that power Sorrento Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Miscellaneous
JavaScript libraries
Translation
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
SEO
Tag managers
Hong Kong
Ireland
Portugal
Frequently asked questions
4.8
40,000 users
